Dobutamine

Product Description

Dobutamine is used as a pharmacological agent and has both ionotropic and chronotropic effects depending on the dose. Because of its inotropic effects on the myocardium through binding and activating the beta-1 receptors selectively.[7] The medication is indicated clinically for decompensated congestive heart failure because of the sympathomimetic effects. Dobutamine's ionotropic effect increases contractility, leading to decreased end-systolic volume and, therefore, increased stroke volume. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK470431/)

Mechanisms of Action: ADRB1 Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Italy | Japan | Jordan | Korea | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: AZIENDA UNITA`NITARIA LOCALE N 12 DI VIAREGGIO
Company Location:
Company CEO:
Additonal Commercial Interests: None